NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Price, News & Analysis $0.87 -0.02 (-2.64%) Closing price 08/13/2026 04:00 PM EasternExtended Trading$0.90 +0.03 (+2.92%) As of 04:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Akebia Therapeutics Stock (NASDAQ:AKBA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Akebia Therapeutics alerts:Sign Up Key Stats Today's Range$0.86▼$0.9550-Day Range$0.84▼$1.4352-Week Range$0.82▼$3.34Volume4.09 million shsAverage Volume4.05 million shsMarket Capitalization$240.97 millionP/E RatioN/ADividend YieldN/APrice Target$3.75Consensus RatingHold Company Overview Akebia Therapeutics, Inc., a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, is focused on the development and commercialization of therapies for patients with kidney disease. The company’s lead product candidate, vadadustat, is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to treat anemia associated with chronic kidney disease in both dialysis-dependent and non-dialysis patients. Akebia’s research and development efforts also extend to preclinical programs targeting nephrology and related metabolic disorders. Since its founding in 2007, Akebia has pursued strategic collaborations to advance its clinical pipeline and expand its market reach. The company has partnered with Otsuka Pharmaceutical for filing and commercialization of vadadustat in the United States, while Mitsubishi Tanabe Pharma holds rights to develop and commercialize the compound in ex-Japan territories. These alliances leverage Akebia’s scientific expertise alongside the global commercialization networks of its partners. In addition to its focus on anemia in kidney disease, Akebia evaluates novel mechanisms of action aimed at improving kidney health and patient outcomes. The company maintains clinical trial sites across North America and engages with healthcare providers, academic institutions and patient advocacy groups to support the design and execution of its studies. Under the leadership of President and Chief Executive Officer John P. Butler, Akebia continues to build its development infrastructure and prepare for potential regulatory milestones.AI Generated. May Contain Errors. Read More Akebia Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreAKBA MarketRank™: Akebia Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 627th out of 911 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingAkebia Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 3 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAkebia Therapeutics has a consensus price target of $3.75, representing about 331.2% upside from its current price of $0.87.Amount of Analyst CoverageAkebia Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Akebia Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Akebia Therapeutics are expected to decrease in the coming year, from ($0.13) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -7.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -7.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkebia Therapeutics has a P/B Ratio of 9.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.23% of the float of Akebia Therapeutics has been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 8.81.Change versus previous monthShort interest in Akebia Therapeutics has recently increased by 0.56%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.06 News SentimentAkebia Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Akebia Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $62,181.00 in company stock.Percentage Held by Insiders4.30% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by Institutions33.92% of the stock of Akebia Therapeutics is held by institutions.Read more about Akebia Therapeutics' insider trading history. Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKBA Stock News HeadlinesWhat is HC Wainwright's Estimate for AKBA FY2026 Earnings?August 10, 2026 | americanbankingnews.comAkebia Therapeutics (NASDAQ:AKBA) Cut to Market Perform at Leerink PartnersAugust 10, 2026 | americanbankingnews.comTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security. The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | Porter & Company (Ad)Akebia plans Vafseo price reset after Dec. 31, 2026 TDAPA as VOICE trial posts win odds 1.16August 6, 2026 | seekingalpha.comAkebia Therapeutics: Q2 Earnings SnapshotAugust 6, 2026 | chron.comAkebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call TranscriptAugust 5, 2026 | seekingalpha.comAkebia Therapeutics Reports Second Quarter 2026 Financial Results and Business HighlightsAugust 5, 2026 | globenewswire.comAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 3, 2026 | globenewswire.comSee More Headlines AKBA Stock Analysis - Frequently Asked Questions How have AKBA shares performed this year? Akebia Therapeutics' stock was trading at $1.61 at the start of the year. Since then, AKBA stock has decreased by 46.0% and is now trading at $0.8696. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) issued its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The biopharmaceutical company earned $49.13 million during the quarter, compared to the consensus estimate of $48.85 million. Akebia Therapeutics had a negative net margin of 13.54% and a negative trailing twelve-month return on equity of 88.88%. Read the conference call transcript. When did Akebia Therapeutics IPO? Akebia Therapeutics (AKBA) raised $91 million in an initial public offering (IPO) on Thursday, March 20th 2014. The company issued 5,882,353 shares at $14.00-$17.00 per share. Who are Akebia Therapeutics' major shareholders? Top institutional investors of Akebia Therapeutics include BlackRock Inc. (7.45%), Hennion & Walsh Asset Management Inc. (0.31%), Bank of New York Mellon Corp (0.23%) and Virtus Advisers LLC (0.11%). Insiders that own company stock include John P Butler, Steven Keith Burke, Michel Dahan, Nicole R Hadas, Erik Ostrowski, Nicholas Grund and Richard C Malabre. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and ExxonMobil (XOM). Company Calendar Last Earnings8/05/2026Today8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 8 days, AKBA's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:AKBA CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees430Year Founded2007Price Target and Rating Average Price Target for Akebia Therapeutics$3.75 High Price Target$6.00 Low Price Target$1.00 Potential Upside/Downside+331.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.34 million Net Margins-13.54% Pretax Margin-12.71% Return on Equity-88.88% Return on Assets-7.74% Debt Debt-to-Equity Ratio0.99 Current Ratio1.43 Quick Ratio1.35 Sales & Book Value Annual Sales$219.06 million Price / Sales1.10 Cash FlowN/A Price / Cash FlowN/A Book Value$0.09 per share Price / Book9.66Miscellaneous Outstanding Shares277,106,000Free Float265,190,000Market Cap$240.97 million OptionableOptionable Beta0.26 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:AKBA) was last updated on 8/14/2026 by MarketBeat.com Staff. From Our PartnersThe Starlink of EnergyA portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...Monument Traders Alliance | SponsoredTrump’s New Currency ResetTrump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
